Ganymed Completes Recruitment for Randomized Phase 2 FAST Trial of IMAB362 for Gastroesophageal Cancer
Ganymed Pharmaceuticals AG, a biopharmaceutical company developing Ideal Monoclonal Antibodies (IMABs) for the treatment…
Ganymed Pharmaceuticals AG, a biopharmaceutical company developing Ideal Monoclonal Antibodies (IMABs) for the treatment…
Ganymed Pharmaceuticals AG announced today that its Ideal Monoclonal Antibody IMAB362 demonstrated significant safety an…
Ganymed Pharmaceuticals AG announced today that the Food and Drug Administration (FDA) and the European Medicines Agency…